Mancini Anthony reported option exercise involving 810 derivative units of Revolution Medicines, Inc. at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
See Remarks
See Remarks
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
810Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
90,505Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 12, 2026, 6:00 PM ET3-day reporting delay
Accession
0001193125-26-458844Code M · Transaction 399697
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Option exercise1$0.00$0Trade 399698
Nov 9, 2026Sell811$200.00−$162,200Trade 399696
Nov 9, 2026Option exercise810$33.62$27,232.20Trade 399694
Nov 9, 2026Option exercise1$102.02$102.02Trade 399695
5 transaction rows in this filing. Joint filers share the same rows.

RVMD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RVMD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +7.6%1w ago +6.7%1d ago +9%
Returns since7d30d90d180d1y

Footnotes in full

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026. F2: Includes 39,575 restricted stock units. F3: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. F4: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.